Transcode Therapeutics EBITDA per Employee
The EBITDA per Employee of Transcode Therapeutics (RNAZ) as of Oct 12, 2026 is -1.47 M USD. In the previous year, EBITDA per Employee was -880,429.42 USD — a change of 67.26% (lower).
Get this data via API
Financial Data API
EBITDA per Employee
-1.47 MUSD
YoY
67.26%
Last updated:
The Transcode Therapeutics EBITDA per Employee history
3 Years
10 Years
25 Years
Max
| YEAR | EBITDA per Employee | YoY |
|---|---|---|
| -1.47 MUSD | +67.26% | |
| -880,429.42USD | -13.85% | |
| -1.02 MUSD | +4.03% | |
| -982,411.21USD | +176.60% | |
| -355,175.11USD | +828.75% | |
| -38,242.32USD | +59.04% | |
| -24,045.53USD | +18.98% | |
| -20,210.32USD | — |
Transcode Therapeutics Stock analysis
Frequently Asked Questions about Transcode Therapeutics stock
EBITDA per Employee of Transcode Therapeutics is -1.47 M USD in 2025.
EBITDA per Employee of Transcode Therapeutics changed from -880,429.42 USD to -1.47 M USD, representing a 67.26% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of EBITDA per Employee Transcode Therapeutics since 2006 – with annual values, charts, and detailed analysis.
EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.
EBITDA per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's Transcode Therapeutics historically and in real time.
Workforce — Transcode Therapeutics
All Key Metrics — Transcode Therapeutics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth